Stockreport

Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update

Grace Therapeutics, Inc.  (GRCE) 
PDF FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemor [Read more]